OncoZenge AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	0.94	3.71	3.86	12.63	29.14	51.22
Cash & Short-Term Investments	0.94	3.71	3.86	12.63	29.14	51.22
Cash Growth	-27.74%	-3.86%	-69.41%	-56.67%	-43.11%	412.23%
Other Receivables	1.78	2.54	0.52	0.64	0.71	0.85
Receivables	1.78	2.54	0.52	0.64	0.71	0.85
Prepaid Expenses	2.24	2.23	0.2	0.22	0.19	0.06
Total Current Assets	4.95	8.49	4.58	13.49	30.04	52.13
Other Intangible Assets	6.85	6.85	6.85	6.85	6.85	6.85
Long-Term Deferred Tax Assets	-	-	-	-	-	3.08
Long-Term Deferred Charges	-	-	-	-	-	23.17
Other Long-Term Assets	-	9.06	-	-	-	-
Total Assets	11.8	24.4	11.43	20.34	36.89	85.23
Accounts Payable	2.59	6.8	0.66	0.93	1.65	4.02
Accrued Expenses	1.27	1.55	0.78	0.66	1.01	0.5
Other Current Liabilities	0.08	0.07	0.05	0.11	0.26	0.39
Total Current Liabilities	3.94	8.42	1.48	1.7	2.92	4.9
Long-Term Debt	7.5	7.5	-	-	-	-
Total Liabilities	11.44	15.92	1.48	1.7	2.92	4.9
Common Stock	1.56	1.41	1.3	1.3	1.3	1.3
Additional Paid-In Capital	97.63	98.77	84.41	84.41	83.84	83.54
Retained Earnings	-98.83	-91.7	-75.76	-67.07	-51.17	-4.52
Shareholders' Equity	0.36	8.48	9.95	18.64	33.97	80.32
Total Liabilities & Equity	11.8	24.4	11.43	20.34	36.89	85.23
Total Debt	7.5	7.5	-	-	-	-
Net Cash (Debt)	-6.57	-3.79	3.86	12.63	29.14	51.22
Net Cash Growth	-	-	-69.41%	-56.67%	-43.11%	412.23%
Net Cash Per Share	-0.52	-0.31	0.33	1.08	2.49	4.35
Filing Date Shares Outstanding	14.05	12.65	11.71	11.71	11.71	11.71
Total Common Shares Outstanding	14.05	12.65	11.71	11.71	11.71	11.71
Working Capital	1.01	0.06	3.1	11.79	27.12	47.23
Book Value Per Share	0.03	0.67	0.85	1.59	2.90	6.86
Tangible Book Value	-6.49	1.63	3.1	11.79	27.12	73.47
Tangible Book Value Per Share	-0.46	0.13	0.26	1.01	2.32	6.27